Spero Therapeutics (NASDAQ:SPRO) Coverage Initiated at Janney Montgomery Scott

Janney Montgomery Scott initiated coverage on shares of Spero Therapeutics (NASDAQ:SPRO) in a research report released on Monday morning, BenzingaRatingsTable reports. The firm issued a buy rating on the stock.

Several other brokerages have also recently commented on SPRO. TheStreet cut shares of Spero Therapeutics from a c- rating to a d+ rating in a research report on Monday, July 29th. Zacks Investment Research cut shares of Spero Therapeutics from a buy rating to a hold rating in a research report on Friday, August 16th. HC Wainwright reiterated a buy rating and issued a $28.00 price target on shares of Spero Therapeutics in a research report on Wednesday, September 4th. Finally, ValuEngine upgraded shares of Spero Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Spero Therapeutics has an average rating of Hold and a consensus target price of $21.20.

Shares of NASDAQ SPRO opened at $12.44 on Monday. Spero Therapeutics has a fifty-two week low of $5.52 and a fifty-two week high of $14.48. The firm’s 50-day simple moving average is $9.97 and its 200 day simple moving average is $11.46. The company has a quick ratio of 13.66, a current ratio of 13.66 and a debt-to-equity ratio of 0.04. The stock has a market cap of $207.08 million, a P/E ratio of -4.78 and a beta of 2.08.



Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%. The company had revenue of $2.16 million for the quarter, compared to the consensus estimate of $6.95 million. On average, sell-side analysts anticipate that Spero Therapeutics will post -2.9 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC bought a new stake in Spero Therapeutics in the second quarter worth about $25,000. Marshall Wace LLP bought a new stake in Spero Therapeutics in the first quarter worth about $39,000. D.A. Davidson & CO. bought a new stake in Spero Therapeutics in the second quarter worth about $115,000. Wells Fargo & Company MN raised its position in Spero Therapeutics by 187.9% in the second quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after acquiring an additional 8,915 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Spero Therapeutics by 30.7% in the second quarter. Charles Schwab Investment Management Inc. now owns 25,118 shares of the company’s stock worth $290,000 after acquiring an additional 5,895 shares in the last quarter. Hedge funds and other institutional investors own 50.97% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

See Also: Trading Penny Stocks

Analyst Recommendations for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.